General Information:

Id: 3,877
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
male
article
Reference: Jula A et al.(2005) Effects of diet and simvastatin on fatty acid composition in hypercholesterolemic men: a randomized controlled trial Arterioscler. Thromb. Vasc. Biol. 25: 1952-1959 [PMID: 16020749]

Interaction Information:

Comment A diet low in saturated fatty acids and enriched in monounsaturated and polyunsaturated fatty acids (PUFAs), especially alpha-linolenic acid, cereals, fruits, berries, and vegetables was used in the study. Dietary treatment did not change serum total fatty acid concentration, but it decreased the proportion of palmitic acid (C16:0) from total fatty acids by 3.3% and that of stearic acid (C18:0) by 3.7%. The proportions of oleic acid (C18:1), alpha-linolenic acid (C18:3 n-3), and the sum of C18-22 polyunsaturated n-3 fatty acids were increased by 4.2%, 29.8%, and 9.3%, respectively.
Formal Description
Interaction-ID: 39057

environment

dietary treatment

NOT affects_activity of

in blood serum
Comment A diet low in saturated fatty acids and enriched in monounsaturated and polyunsaturated fatty acids (PUFAs), especially alpha-linolenic acid, cereals, fruits, berries, and vegetables was used in the study. Dietary treatment did not change serum total fatty acid concentration, but it decreased the proportion of palmitic acid (C16:0) from total fatty acids by 3.3% and that of stearic acid (C18:0) by 3.7%. The proportions of oleic acid (C18:1), alpha-linolenic acid (C18:3 n-3), and the sum of C18-22 polyunsaturated n-3 fatty acids were increased by 4.2%, 29.8%, and 9.3%, respectively.
Formal Description
Interaction-ID: 39061

environment

dietary treatment

decreases_quantity of

drug/chemical compound

Palmitic acid

in blood serum
Drugbank entries Show/Hide entries for
Comment A diet low in saturated fatty acids and enriched in monounsaturated and polyunsaturated fatty acids (PUFAs), especially alpha-linolenic acid, cereals, fruits, berries, and vegetables was used in the study. Dietary treatment did not change serum total fatty acid concentration, but it decreased the proportion of palmitic acid (C16:0) from total fatty acids by 3.3% and that of stearic acid (C18:0) by 3.7%. The proportions of oleic acid (C18:1), alpha-linolenic acid (C18:3 n-3), and the sum of C18-22 polyunsaturated n-3 fatty acids were increased by 4.2%, 29.8%, and 9.3%, respectively.
Formal Description
Interaction-ID: 39062

environment

dietary treatment

decreases_quantity of

drug/chemical compound

Stearic acid

in blood serum
Drugbank entries Show/Hide entries for
Comment A diet low in saturated fatty acids and enriched in monounsaturated and polyunsaturated fatty acids (PUFAs), especially alpha-linolenic acid, cereals, fruits, berries, and vegetables was used in the study. Dietary treatment did not change serum total fatty acid concentration, but it decreased the proportion of palmitic acid (C16:0) from total fatty acids by 3.3% and that of stearic acid (C18:0) by 3.7%. The proportions of oleic acid (C18:1), alpha-linolenic acid (C18:3 n-3), and the sum of C18-22 polyunsaturated n-3 fatty acids were increased by 4.2%, 29.8%, and 9.3%, respectively.
Formal Description
Interaction-ID: 39063

environment

dietary treatment

increases_quantity of

drug/chemical compound

Oleic acid

in blood serum
Drugbank entries Show/Hide entries for
Comment A diet low in saturated fatty acids and enriched in monounsaturated and polyunsaturated fatty acids (PUFAs), especially alpha-linolenic acid, cereals, fruits, berries, and vegetables was used in the study. Dietary treatment did not change serum total fatty acid concentration, but it decreased the proportion of palmitic acid (C16:0) from total fatty acids by 3.3% and that of stearic acid (C18:0) by 3.7%. The proportions of oleic acid (C18:1), alpha-linolenic acid (C18:3 n-3), and the sum of C18-22 polyunsaturated n-3 fatty acids were increased by 4.2%, 29.8%, and 9.3%, respectively.
Formal Description
Interaction-ID: 39064

environment

dietary treatment

increases_quantity of

drug/chemical compound

alpha-Linolenic acid

in blood serum
Drugbank entries Show/Hide entries for
Comment A diet low in saturated fatty acids and enriched in monounsaturated and polyunsaturated fatty acids (PUFAs), especially alpha-linolenic acid, cereals, fruits, berries, and vegetables was used in the study. Dietary treatment did not change serum total fatty acid concentration, but it decreased the proportion of palmitic acid (C16:0) from total fatty acids by 3.3% and that of stearic acid (C18:0) by 3.7%. The proportions of oleic acid (C18:1), alpha-linolenic acid (C18:3 n-3), and the sum of C18-22 polyunsaturated n-3 fatty acids were increased by 4.2%, 29.8%, and 9.3%, respectively.
Formal Description
Interaction-ID: 39065

environment

dietary treatment

increases_quantity of

drug/chemical compound

Polyunsaturated fatty acid, omega-3, C18-C22

in blood serum
Comment Simvastatin decreased serum total fatty acid concentration by 13.0% and the concentrations of several fatty acids, including alpha-linolenic, eicosatetraenoic (C20:4 n-3), and docosahexaenoic (C22:6 n-3) acid. It decreased the proportion of myristic acid (C14:0) from total fatty acids by 11.5%, and that of palmitic, linoleic (C18:2 n-6) and alpha-linolenic acid by 2.0%, 5.3%, and 6.8%, respectively. The proportions of gamma-linolenic (C18:3 n-6), dihomo-gamma-linolenic (C20:3 n-6), and arachidonic acid (C20:4 n-6) from total fatty acids in serum were increased by 11.1%, 4.2%, and 14.2%, respectively. The effects of dietary treatment and simvastatin on the proportions of serum fatty acids were independent and additive.
Formal Description
Interaction-ID: 39067

drug/chemical compound

Simvastatin

increases_activity of

in blood serum
Drugbank entries Show/Hide entries for Simvastatin
Comment Simvastatin decreased serum total fatty acid concentration by 13.0% and the concentrations of several fatty acids, including alpha-linolenic, eicosatetraenoic (C20:4 n-3), and docosahexaenoic (C22:6 n-3) acid. It decreased the proportion of myristic acid (C14:0) from total fatty acids by 11.5%, and that of palmitic, linoleic (C18:2 n-6) and alpha-linolenic acid by 2.0%, 5.3%, and 6.8%, respectively. The proportions of gamma-linolenic (C18:3 n-6), dihomo-gamma-linolenic (C20:3 n-6), and arachidonic acid (C20:4 n-6) from total fatty acids in serum were increased by 11.1%, 4.2%, and 14.2%, respectively. The effects of dietary treatment and simvastatin on the proportions of serum fatty acids were independent and additive.
Formal Description
Interaction-ID: 39070

drug/chemical compound

Simvastatin

decreases_quantity of

drug/chemical compound

alpha-Linolenic acid

in blood serum
Drugbank entries Show/Hide entries for Simvastatin or alpha-Linolenic acid
Comment Simvastatin decreased serum total fatty acid concentration by 13.0% and the concentrations of several fatty acids, including alpha-linolenic, eicosatetraenoic (C20:4 n-3), and docosahexaenoic (C22:6 n-3) acid. It decreased the proportion of myristic acid (C14:0) from total fatty acids by 11.5%, and that of palmitic, linoleic (C18:2 n-6) and alpha-linolenic acid by 2.0%, 5.3%, and 6.8%, respectively. The proportions of gamma-linolenic (C18:3 n-6), dihomo-gamma-linolenic (C20:3 n-6), and arachidonic acid (C20:4 n-6) from total fatty acids in serum were increased by 11.1%, 4.2%, and 14.2%, respectively. The effects of dietary treatment and simvastatin on the proportions of serum fatty acids were independent and additive.
Formal Description
Interaction-ID: 39071

drug/chemical compound

Simvastatin

decreases_quantity of

drug/chemical compound

Eicosatetraenoic acid

in blood serum
Drugbank entries Show/Hide entries for Simvastatin
Comment Simvastatin decreased serum total fatty acid concentration by 13.0% and the concentrations of several fatty acids, including alpha-linolenic, eicosatetraenoic (C20:4 n-3), and docosahexaenoic (C22:6 n-3) acid. It decreased the proportion of myristic acid (C14:0) from total fatty acids by 11.5%, and that of palmitic, linoleic (C18:2 n-6) and alpha-linolenic acid by 2.0%, 5.3%, and 6.8%, respectively. The proportions of gamma-linolenic (C18:3 n-6), dihomo-gamma-linolenic (C20:3 n-6), and arachidonic acid (C20:4 n-6) from total fatty acids in serum were increased by 11.1%, 4.2%, and 14.2%, respectively. The effects of dietary treatment and simvastatin on the proportions of serum fatty acids were independent and additive.
Formal Description
Interaction-ID: 39072

drug/chemical compound

Simvastatin

decreases_quantity of

drug/chemical compound

Docosahexaenoic acid

in blood serum
Drugbank entries Show/Hide entries for Simvastatin
Comment Simvastatin decreased serum total fatty acid concentration by 13.0% and the concentrations of several fatty acids, including alpha-linolenic, eicosatetraenoic (C20:4 n-3), and docosahexaenoic (C22:6 n-3) acid. It decreased the proportion of myristic acid (C14:0) from total fatty acids by 11.5%, and that of palmitic, linoleic (C18:2 n-6) and alpha-linolenic acid by 2.0%, 5.3%, and 6.8%, respectively. The proportions of gamma-linolenic (C18:3 n-6), dihomo-gamma-linolenic (C20:3 n-6), and arachidonic acid (C20:4 n-6) from total fatty acids in serum were increased by 11.1%, 4.2%, and 14.2%, respectively. The effects of dietary treatment and simvastatin on the proportions of serum fatty acids were independent and additive.
Formal Description
Interaction-ID: 39073

drug/chemical compound

Simvastatin

decreases_quantity of

drug/chemical compound

Myristic acid

in blood serum
Drugbank entries Show/Hide entries for Simvastatin or Myristic acid
Comment Simvastatin decreased serum total fatty acid concentration by 13.0% and the concentrations of several fatty acids, including alpha-linolenic, eicosatetraenoic (C20:4 n-3), and docosahexaenoic (C22:6 n-3) acid. It decreased the proportion of myristic acid (C14:0) from total fatty acids by 11.5%, and that of palmitic, linoleic (C18:2 n-6) and alpha-linolenic acid by 2.0%, 5.3%, and 6.8%, respectively. The proportions of gamma-linolenic (C18:3 n-6), dihomo-gamma-linolenic (C20:3 n-6), and arachidonic acid (C20:4 n-6) from total fatty acids in serum were increased by 11.1%, 4.2%, and 14.2%, respectively. The effects of dietary treatment and simvastatin on the proportions of serum fatty acids were independent and additive.
Formal Description
Interaction-ID: 39074

drug/chemical compound

Simvastatin

decreases_quantity of

drug/chemical compound

Palmitic acid

in blood serum
Drugbank entries Show/Hide entries for Simvastatin or Palmitic acid
Comment Simvastatin decreased serum total fatty acid concentration by 13.0% and the concentrations of several fatty acids, including alpha-linolenic, eicosatetraenoic (C20:4 n-3), and docosahexaenoic (C22:6 n-3) acid. It decreased the proportion of myristic acid (C14:0) from total fatty acids by 11.5%, and that of palmitic, linoleic (C18:2 n-6) and alpha-linolenic acid by 2.0%, 5.3%, and 6.8%, respectively. The proportions of gamma-linolenic (C18:3 n-6), dihomo-gamma-linolenic (C20:3 n-6), and arachidonic acid (C20:4 n-6) from total fatty acids in serum were increased by 11.1%, 4.2%, and 14.2%, respectively. The effects of dietary treatment and simvastatin on the proportions of serum fatty acids were independent and additive.
Formal Description
Interaction-ID: 39075

drug/chemical compound

Simvastatin

decreases_quantity of

drug/chemical compound

Linoleic acid

in blood serum
Drugbank entries Show/Hide entries for Simvastatin
Comment Simvastatin decreased serum total fatty acid concentration by 13.0% and the concentrations of several fatty acids, including alpha-linolenic, eicosatetraenoic (C20:4 n-3), and docosahexaenoic (C22:6 n-3) acid. It decreased the proportion of myristic acid (C14:0) from total fatty acids by 11.5%, and that of palmitic, linoleic (C18:2 n-6) and alpha-linolenic acid by 2.0%, 5.3%, and 6.8%, respectively. The proportions of gamma-linolenic (C18:3 n-6), dihomo-gamma-linolenic (C20:3 n-6), and arachidonic acid (C20:4 n-6) from total fatty acids in serum were increased by 11.1%, 4.2%, and 14.2%, respectively. The effects of dietary treatment and simvastatin on the proportions of serum fatty acids were independent and additive.
Formal Description
Interaction-ID: 39076

drug/chemical compound

Simvastatin

decreases_quantity of

drug/chemical compound

alpha-Linolenic acid

in blood serum
Drugbank entries Show/Hide entries for Simvastatin or alpha-Linolenic acid
Comment Simvastatin decreased serum total fatty acid concentration by 13.0% and the concentrations of several fatty acids, including alpha-linolenic, eicosatetraenoic (C20:4 n-3), and docosahexaenoic (C22:6 n-3) acid. It decreased the proportion of myristic acid (C14:0) from total fatty acids by 11.5%, and that of palmitic, linoleic (C18:2 n-6) and alpha-linolenic acid by 2.0%, 5.3%, and 6.8%, respectively. The proportions of gamma-linolenic (C18:3 n-6), dihomo-gamma-linolenic (C20:3 n-6), and arachidonic acid (C20:4 n-6) from total fatty acids in serum were increased by 11.1%, 4.2%, and 14.2%, respectively. The effects of dietary treatment and simvastatin on the proportions of serum fatty acids were independent and additive.
Formal Description
Interaction-ID: 39077

drug/chemical compound

Simvastatin

increases_quantity of

drug/chemical compound

gamma-Linolenic acid

in blood serum
Drugbank entries Show/Hide entries for Simvastatin
Comment Simvastatin decreased serum total fatty acid concentration by 13.0% and the concentrations of several fatty acids, including alpha-linolenic, eicosatetraenoic (C20:4 n-3), and docosahexaenoic (C22:6 n-3) acid. It decreased the proportion of myristic acid (C14:0) from total fatty acids by 11.5%, and that of palmitic, linoleic (C18:2 n-6) and alpha-linolenic acid by 2.0%, 5.3%, and 6.8%, respectively. The proportions of gamma-linolenic (C18:3 n-6), dihomo-gamma-linolenic (C20:3 n-6), and arachidonic acid (C20:4 n-6) from total fatty acids in serum were increased by 11.1%, 4.2%, and 14.2%, respectively. The effects of dietary treatment and simvastatin on the proportions of serum fatty acids were independent and additive.
Formal Description
Interaction-ID: 39079

drug/chemical compound

Simvastatin

increases_quantity of

drug/chemical compound

Eicosatrienoic acid

in blood serum
Drugbank entries Show/Hide entries for Simvastatin
Comment Simvastatin decreased serum total fatty acid concentration by 13.0% and the concentrations of several fatty acids, including alpha-linolenic, eicosatetraenoic (C20:4 n-3), and docosahexaenoic (C22:6 n-3) acid. It decreased the proportion of myristic acid (C14:0) from total fatty acids by 11.5%, and that of palmitic, linoleic (C18:2 n-6) and alpha-linolenic acid by 2.0%, 5.3%, and 6.8%, respectively. The proportions of gamma-linolenic (C18:3 n-6), dihomo-gamma-linolenic (C20:3 n-6), and arachidonic acid (C20:4 n-6) from total fatty acids in serum were increased by 11.1%, 4.2%, and 14.2%, respectively. The effects of dietary treatment and simvastatin on the proportions of serum fatty acids were independent and additive.
Formal Description
Interaction-ID: 39086

drug/chemical compound

Simvastatin

increases_quantity of

drug/chemical compound

Arachidonic acid

in blood serum
Drugbank entries Show/Hide entries for Simvastatin or Arachidonic acid
Comment Simvastatin increased the proportion of long-chain fatty acids (C20-22) from total fatty acids by 9.0%, and the ratios of stearic to palmitic acid (reflecting elongase activity) by 7.6%, gamma-linolenic to linoleic acid (reflecting Delta6 desaturase activity) by 17.0%, and the ratios of arachidonic to dihomo-gamma-linolenic and eicosapentaenoic to eicosatetraenoic acid, both reflecting Delta5 desaturase activity, by 10.0% and 26.9%, respectively.
Formal Description
Interaction-ID: 39087

drug/chemical compound

Simvastatin

increases_activity of

gene/protein

ELOVL6

Drugbank entries Show/Hide entries for Simvastatin
Comment Simvastatin increased the proportion of long-chain fatty acids (C20-22) from total fatty acids by 9.0%, and the ratios of stearic to palmitic acid (reflecting elongase activity) by 7.6%, gamma-linolenic to linoleic acid (reflecting Delta6 desaturase activity) by 17.0%, and the ratios of arachidonic to dihomo-gamma-linolenic and eicosapentaenoic to eicosatetraenoic acid, both reflecting Delta5 desaturase activity, by 10.0% and 26.9%, respectively.
Formal Description
Interaction-ID: 39088

drug/chemical compound

Simvastatin

increases_activity of

gene/protein

FADS2

Drugbank entries Show/Hide entries for Simvastatin or FADS2
Comment Simvastatin increased the proportion of long-chain fatty acids (C20-22) from total fatty acids by 9.0%, and the ratios of stearic to palmitic acid (reflecting elongase activity) by 7.6%, gamma-linolenic to linoleic acid (reflecting Delta6 desaturase activity) by 17.0%, and the ratios of arachidonic to dihomo-gamma-linolenic and eicosapentaenoic to eicosatetraenoic acid, both reflecting Delta5 desaturase activity, by 10.0% and 26.9%, respectively.
Formal Description
Interaction-ID: 39089

drug/chemical compound

Simvastatin

increases_activity of

gene/protein

FADS1

Drugbank entries Show/Hide entries for Simvastatin or FADS1
Comment Dietary treatment neither increased the proportion of long-chain fatty acids nor affected the indicators of fatty acid elongase and Delta6- and Delta5-desaturase enzyme activities.
Formal Description
Interaction-ID: 39090

environment

dietary treatment

NOT affects_activity of

gene/protein

ELOVL6

Comment Dietary treatment neither increased the proportion of long-chain fatty acids nor affected the indicators of fatty acid elongase and Delta6- and Delta5-desaturase enzyme activities.
Formal Description
Interaction-ID: 39091

environment

dietary treatment

NOT affects_activity of

gene/protein

FADS2

Drugbank entries Show/Hide entries for FADS2
Comment Dietary treatment neither increased the proportion of long-chain fatty acids nor affected the indicators of fatty acid elongase and Delta6- and Delta5-desaturase enzyme activities.
Formal Description
Interaction-ID: 39092

environment

dietary treatment

NOT affects_activity of

gene/protein

FADS1

Drugbank entries Show/Hide entries for FADS1
Comment Increased formation of long-chain polyunsaturated fatty acids and their metabolites may contribute a substantial part of the pleiotropic effects of simvastatin.
Formal Description
Interaction-ID: 39093

drug/chemical compound

Simvastatin

increases_activity of

process

long-chain polyunsaturated fatty acid biosynthetic process

Drugbank entries Show/Hide entries for Simvastatin